GW Link

Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Prevention Beyond the Pipeline

Grants to USA, Canada, and International Researchers and Clinicians
for Studies Related to the Prevention of Alzheimer's and Dementia

Agency Type:

Foundation / Corporation

Funding Source:

Add to My Calendar 

Alzheimer's Drug Discovery Foundation (ADDF)

LOI Date:


Deadline Date:

11/08/19 5:00 PM EST Receipt


Request a Grant Writer

Grants to USA, Canada, and International postdoctoral fellows, clinicians, and researchers working in nonprofits, IHEs, academic medical centers, and biotechnology companies for research on the prevention of Alzheimer's and related dementias. Applicants must submit an LOI prior to submitting a full application. Funding is intended to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Funding Priorities: 

  • Consortium of Cohorts for Alzheimer's Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. 
  • Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition. Methods may include randomized trials or epidemiology.
  • Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.

The strongest clinical trial applications will possess composition of matter patents (for novel drug candidates) or strategies for developing intellectual property (for repurposed and repositioned drugs), and include preclinical packages with: i) robust target engagement and efficacy data in relevant animal model(s) and ii) demonstrated blood-brain barrier permeability (CNS targeted therapies).

GrantWatch ID#:

GrantWatch ID#: 182777

Estimated Size of Grant:

Average Award:
- $50,000 - $100,000 for epidemiological analyses based on scope of research
- Up to $3 million based on stage and scope of research.

Term of Contract:

Average grant duration is one year for epidemiological analyses and varies (multi-year) for clinical trials.

Additional Eligibility Criteria:

Funding is open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working in:
- Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
- Biotechnology companies. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones. Existing companies and new startups are both eligible.

Pre-Application Information:

Letters of Intent are due by October 11, 2019, and invited full proposals are due by November 8, 2019.

It is highly recommended that you access the ADDF Funding Portal to begin the application process well in advance of any deadlines. Please note, new applicants should allow 1-2 business days for registration.

For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.

All clinical trials receiving ADDF funding must register and submit results information for certain "applicable clinical trials" on the Protocol Registration and Results System Information Website:

Application Instructions:

Application and Funding Policies:

Additional information about full proposal stage:

Contact Information:

Before starting your grant application, please review the funding source's website listed below for updates/changes/addendums/conferences/LOIs.

Apply Online:

For program-related inquiries, please contact:
Yuko Hara, PhD, Acting Director, Aging & Alzheimer's Prevention

For application submission inquiries, please contact:
Grants and Mission-Related Investments Team

Alzheimer's Drug Discovery Foundation
57 West 57th Street, Suite 904
New York, NY 10019

URL for Full Text (RFP):

Geographic Focus:

USA: Alabama;   Alaska;   Arizona;   Arkansas;   California;   Colorado;   Connecticut;   Delaware;   Florida;   Georgia;   Hawaii;   Idaho;   Illinois;   Indiana;   Iowa;   Kansas;   Kentucky;   Louisiana;   Maine;   Maryland;   Massachusetts;   Michigan;   Minnesota;   Mississippi;   Missouri;   Montana;   Nebraska;   Nevada;   New Hampshire;   New Jersey;   New Mexico;   New York City;   New York;   North Carolina;   North Dakota;   Ohio;   Oklahoma;   Oregon;   Pennsylvania;   Rhode Island;   South Carolina;   South Dakota;   Tennessee;   Texas;   Utah;   Vermont;   Virginia;   Washington, DC;   Washington;   West Virginia;   Wisconsin;   Wyoming

USA Territories: American Samoa (USA)   Guam (USA)   Puerto Rico (USA)   Virgin Islands (USA)   Northern Mariana Islands (USA)

USA Compact Free Associations: The Federated States of Micronesia (USA)   Marshall Islands (USA)   Republic of Palau (USA)

Canada: Alberta   British Columbia   Manitoba   New Brunswick   Newfoundland and Labrador   Northwest Territories   Nova Scotia   Nunavut   Ontario   Prince Edward Island   Quebec   Saskatchewan   Yukon


International country outside of the USA, Israel and Canada.